Loading
companiesCompany
Valink Therapeutics
Valink designs antibody-drug conjugates that grab two targets at once, aimed at solid tumours that immunotherapy does not reach.
Overview
Valink Therapeutics discovers next-generation antibody-based therapeutics by combining multiple modifications, bispecificity, multivalency and payload conjugation, in a single discovery workflow, generating bispecific antibody-drug conjugates from known tumour targets with new mechanisms of action. Its stated focus is solid tumours poorly served by immunotherapy. Programmes are preclinical as far as public sources show; no sourced financing rounds are recorded.
Headquarters
Boston, MA, US
Funding
All startupsStartupYC W21
Investors
Type
Stage
Startup · Y Combinator Winter 2021
Website
Similar pages
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator and the tag yc.
- CompanyTriomics
Shares Y Combinator and the tag yc.